VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cytokine1 who wrote (8866)	7/23/2001 11:54:57 AM
From: Vector1	Read Replies (1) of 9719

These guys just suck 11:09 (Dow Jones) Corixa (CRXA) dropped 8% after rival Idec Pharmaceuticals (IDPH) announced its cancer drug, Zevalin, will be reviewed by the Oncologic Drugs Advisory Committee of the FDA in September. Shareholders worried that Corixa's cancer drug, Bexxar, could fall behind in the race to market. Corixa still needs to submit more information to the FDA before it can get a panel review. Analysts were skeptical the company would be able to make the September review date and, if not, the next panel meeting is in December. (EGS)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next